[
  {
    "source": "wikipedia",
    "text": "Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. In CLL, the bone marrow makes too many lymphocytes, which are a type of white blood cell. In patients with CLL, B cell lymphocytes can begin to collect in their blood, spleen, lymph nodes, and bone marrow. These cells do not function well and crowd out healthy blood cells. CLL is divided into two main types:",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Many people do not have any symptoms when they are first diagnosed. Those with symptoms (about 5-10% of patients with CLL) may experience the following:",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "While the exact cause of CLL is unknown, having a family member with CLL increases one's risk of developing the disease. Environmental risk factors include exposure to Agent Orange, ionizing radiation, and certain insecticides. The use of tobacco is also associated with an increased risk of having CLL.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Diagnosis is typically based on blood tests that find high numbers of mature lymphocytes and smudge cells.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "When patients with CLL are not experiencing symptoms (i.e. are asymptomatic), they only need careful observation. This is because there is currently no evidence that early intervention can alter the course of the disease.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Patients with CLL have an increased risk of developing serious infections. Doctors often routinely monitor patients for infections, treating them with antibiotics if a bacterial infection is present.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "In patients with significant signs or symptoms, treatment can involve chemotherapy, immunotherapy, or chemoimmunotherapy. The most appropriate treatment is based on the individual's age, physical condition, and whether they have the del(17p) or TP53 mutation.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Bruton tyrosine kinase inhibitors (BTKi), such as ibrutinib, zanubrutinib, and acalabrutinib",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "B-cell lymphoma-2 (BCL-2) inhibitor, venetoclax, plus a CD20 antibody obinutuzumab, OR",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "CLL is the most common type of leukemia in the Western world. It most commonly affects individuals over the age of 65, due to the accumulation of genetic mutations that occur over time. CLL is rarely seen in individuals less than 40 years old. Men are more commonly affected than women, although the average lifetime risk for both genders are similar (around 0.5-1%). It represented less than 1% of deaths from cancer between 1980 and 2015.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Most people are diagnosed as having CLL based on the result of a routine blood test that shows a high white blood cell count, specifically a large increase in the number of circulating lymphocytes. Most commonly, patients have no symptoms at first. In a small number of cases, patients with CLL may present with enlarged lymph nodes, partially in areas around the neck, armpit, or groin.  In rare circumstances, the disease is recognized only after the cancerous cells overwhelm the bone marrow, resulting in low red blood cells, neutrophils, or platelets. This can then result in symptoms such as fever, easy bleeding/bruising, night sweats, weight loss, and increased tiredness. In some instances, the cancerous cells can accumulate in the spleen and result in splenomegaly.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "About 25% of patients with CLL have very low levels of antibodies in their bloodstream (hypogammaglobulinemia) at diagnosis, with several more patients developing this throughout the course of their disease. This decrease in antibodies increases the patient's risk of recurrent infections and other autoimmune complications, such as autoimmune hemolytic anemia and immune thrombocytopenia. Autoimmune hemolytic anemia occurs in about 5-10% of CLL patients, which is when one's own immune system attacks its own red blood cells.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "A more serious complication called Richter's transformation (RT) occurs in 2-10% of patients with CLL. This is a process in which the original CLL cells convert to a far more aggressive disease that has the biology and histopathology of diffuse large B cell lymphoma or less commonly Hodgkin's lymphoma. These patients typically present with a sudden clinical deterioration that can be characterized by unexplained fevers or weight loss, asymmetric and rapid growth of lymph nodes, and/or a significant drop in the number of white blood cells, red blood cells, or platelets. Treatment for RT typically consists of various chemotherapy/chemo-immunotherapy protocols.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "CLL has also been reported to convert into other more aggressive diseases such as lymphoblastic lymphoma, hairy cell leukemia, high grade T cell lymphomas, acute myeloid leukemia, lung cancer, brain cancer, melanoma of the eye or skin, salivary gland tumors, and Kaposi's sarcomas. While some of these conversions have been termed RTs, the World Health Organization and most reviews have defined RT as a conversion of CLL/SLL into a disease with DLBCL or HL histopathology.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Gastrointestinal (GI) involvement can also rarely occur with chronic lymphocytic leukemia. Some of the reported manifestations include intussusception, small intestinal bacterial contamination, colitis, and bleeding. Usually, GI complications with CLL occur after Richter transformation.  Two cases to date have been reported of GI involvement in chronic lymphocytic leukemia without Richter's transformation.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "The exact cause of CLL is unknown. However, family history has been strongly correlated with the development of disease. Environmental factors may also play a role in the development of CLL. For instance, exposure to Agent Orange increases the risk of CLL, and exposure to hepatitis C virus may increase the risk.  There is no clear association between ionizing radiation exposure and the risk of developing CLL. Blood transfusions have been ruled out as a risk factor.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "CLL results from an unusual growth and expansion of white blood cells. This manifestation typically begins with a single hematopoietic stem cell that acquires certain mutations over time that allows it to continue to expand and grow at a faster rate than other cells. Each patient with CLL may be affected by a different set of mutations, making these cells sometimes difficult to target and treat. Some of the most common mutations that have been found in CLL-affected cells include the following: NOTCH1, TP53, ATM, and SF3B1.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "CLL can also be caused by a number of epigenetic changes, which are adaptations that add a tag to specific DNA sequences, rather than altering the sequence itself. In CLL, these changes can be classified into the addition of three different methyl subgroups (na\u00efve B-cell-like, memory B-cell-like, and intermediate), which impact how much that DNA sequence is transcribed. Some relevant genetic mutations may be inherited. Since there is no one single mutation that is associated with CLL in all cases, an individual's susceptibility may be impacted when multiple mutations that are associated with an increase in the risk of CLL are co-inherited. Up until 2020, 45 susceptibility loci have been identified. Of these loci, 93% are linked to the alteration of 30 gene expressions involved in immune response, cell survival, or Wnt signaling.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "As CLL cells accumulate, they begin to promote inflammation and an immunosuppressive environment through the release of different chemical signals.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "CLL is commonly preceded by a pre-cancerous state known as monoclonal B-cell lymphocytosis (MBL). This occurs when there is in an increase in a specific type of white blood cells but the number remains less than 5 billion cells per liter (L) (5 billion/L) of blood. This subtype, termed chronic lymphocytic leukemia-type MBL (CLL-type MBL) is an asymptomatic, indolent, and chronic disorder in which people exhibit a mild increase in the number of circulating B-cell lymphocytes. These B-cells are monoclonal, which means they are produced by a single ancestral B-cell. They share some of the same cell marker proteins, chromosome abnormalities, and gene mutations that are found in CLL.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Low-count MBL has monoclonal B-cell blood counts of <0.5 billion cells/liter (i.e. 0.5 billion/L)",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "High-count MBL has blood monoclonal B-cell counts \u22650.5 billion/L but <5 billion/L.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Low-count MBL rarely if ever progresses to CLL, while high-count CLL/SLL MBL does so at a rate of around 1% per year. Thus, CLL may present in individuals with a long history of having high-count MBL. There is no established treatment for these individuals except monitoring for development of the disorder's various complications (see treatment of MBL complications) and for their progression to CLL.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "The diagnosis of CLL is based on the demonstration of an abnormal population of B lymphocytes in the blood, bone marrow, or tissues that display an unusual but characteristic pattern of molecules on the cell surface. CLL is usually first suspected by a diagnosis of lymphocytosis, an increase in a type of white blood cell, on a complete blood count test. This frequently is an incidental finding on a routine physician visit. Most often the lymphocyte count is greater than 5000 cells per microliter (\u03bcL) of blood but can be much higher. The presence of lymphocytosis in a person who is elderly should raise strong suspicion for CLL, and a confirmatory diagnostic test, in particular flow cytometry should be performed unless clinically unnecessary.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "In order to be diagnosed with CLL, the patient must have a white blood cell count greater than 5 billion cells per liter (L) (5 billion/L) of blood. If CLL-type cells are mainly found in the lymph nodes or lymphoid tissue (such as the spleen), a diagnosis of small lymphocytic lymphoma (SLL) is made. When these cancerous cells appear mostly in the blood, the disease is classified as CLL.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Staging, which helps determine the extent of the disease, is done using one of two systems: the Rai staging system (most commonly used in the United States) or the Binet classification(most commonly used in Europe). These systems are simple, requiring the use of only physical examination and blood test results.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Low-risk disease (formerly Stage 0): characterized by lymphocytosis with cancer cells in the blood and/or bone marrow without lymphadenopathy, hepatosplenomegaly, anemia, or thrombocytopenia",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Intermediate-risk disease (formerly Stage I/II): characterized by lymphocytosis, swollen lymph nodes (may be palpable or not), spleen enlargement, and/or liver enlargement",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "High-risk disease (formerly Stage III/IV): characterized by lymphocytosis with associated anemia (hemoglobin <11 g/dL) OR thrombocytopenia (<100,000/mm3) with or without lymphadenopathy, hepatomegaly, splenomegaly, or anemia",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "This classification system is based on the number of areas within the body that have been affected and the presence of anemia or thrombocytopenia. Areas of involvement include the (1) head and neck (considered one), (2) one or both of the armpits, (3) the groin, (4) the spleen, and (5) the liver. They are considered affected if a lymph node greater than 1 cm in diameter is present and/or the spleen or liver are palpable.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Clinical stage A: characterized by no anemia (Hb > 10 g/dL) or thrombocytopenia (platelets > 100 billion/L) and no greater than two areas of lymphoid involvement (described above)",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Clinical stage B: characterized by no anemia (Hb > 10 g/dL) or thrombocytopenia (platelets > 100 billion/L) with three or more areas of lymphoid involvement",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Clinical stage C: characterized by anemia (Hb < 10 g/dL) and/or thrombocytopenia (platelets < 100 billion/L) regardless of the number of areas of lymph node or organ enlargement",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Array-based karyotyping is a cost-effective alternative to FISH for detecting chromosomal abnormalities in CLL. Several clinical validation studies have shown >95% concordance with the standard CLL FISH panel.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "=== Molecular examination of peripheral blood and flow cytometry ===",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "The combination of the microscopic examination of the peripheral blood and analysis of the lymphocytes by flow cytometry to confirm clonality and molecular expression is needed to establish the diagnosis of CLL. Both are easily accomplished with a small sample of blood.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "A flow cytometer instrument can examine the expression of molecules on individual cells. This requires the use of specific antibodies to cell-surface molecules that have fluorescent tags that are recognized by the instrument. In CLL, the lymphocytes are all genetically identical since they are derived from the same B cell lineage. CLL cells can express the typical B-cell markers such as CD19 and CD20, as well as abnormal surface markers such as CD5 and CD23.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "On a peripheral blood smear, CLL cells resemble normal lymphocytes, although slightly smaller. They are also very fragile and susceptible to breaking when smeared onto a glass slide, giving rise to \"smudge\" or \"smear\" cells, which are a hallmark of the disease. Smudge cells are a result of CLL cells lacking vimentin, a type of cytoskeleton proteins which is a structural component in a cell which maintains the cell's internal shape and mechanical resilience).",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "The atypical molecular pattern on the surface of the cell includes the co-expression of cell surface markers clusters of differentiation 5 (CD5) and 23. In addition, all the CLL cells within one individual are clonal, that is, genetically identical. In practice, this is inferred by the detection of only one of the mutually exclusive antibody light chains, kappa or lambda, on the entire population of the abnormal B cells. Normal B lymphocytes consist of a stew of different antibody-producing cells, resulting in a mixture of both kappa- and lambda-expressing cells. The lack of the normal distribution of these B cells is one basis for demonstrating clonality, the key element for establishing a diagnosis of any B cell malignancy (B cell non-Hodgkin lymphoma). The Matutes's CLL score allows the identification of a homogeneous subgroup of classical CLL, that differs from atypical/mixed CLL for the five markers' expression (CD5, CD23, FMC7, CD22, and immunoglobulin light chain)",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Matutes's CLL scoring system is very helpful for the differential diagnosis between classical CLL and the other B cell chronic lymphoproliferative disorders, but not for the immunological distinction between mixed/atypical CLL and mantle cell lymphoma (MCL malignant B cells). Discrimination between CLL and MCL can be improved by adding non-routine markers such as CD54 and CD200. Among routine markers, the most discriminating feature is the CD20/CD23 mean fluorescence intensity ratio. FMC7 expression can be misleading for borderline cases.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "In the past, cases with similar microscopic appearance in the blood but with a T cell phenotype were referred to as T-cell CLL. However, these are now recognized as a separate disease group and are currently classified as T-cell prolymphocytic leukemias (T-PLL). An accurate diagnosis of T-PLL is important as it is a rare and aggressive disease.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "CLL should not be confused with acute lymphoblastic leukemia, a highly aggressive leukemia most commonly diagnosed in children, and highly treatable in the pediatric setting.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Hematologic disorders that may resemble CLL in their clinical presentation, behavior, and microscopic appearance include mantle cell lymphoma, marginal zone lymphoma, B cell prolymphocytic leukemia, and lymphoplasmacytic lymphoma.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "B cell prolymphocytic leukemia, a related, but more aggressive disorder, has cells with similar phenotype, but are significantly larger than normal lymphocytes and have a prominent nucleolus. The distinction is important as the prognosis and therapy differ from CLL.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Hairy cell leukemia is also a neoplasm of B lymphocytes, but the neoplastic cells have a distinct morphology under the microscope (hairy cell leukemia cells have delicate, hair-like projections on their surfaces) and unique marker molecule expression.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "All the B cell malignancies of the blood and bone marrow can be differentiated from one another by the combination of cellular microscopic morphology, marker molecule expression, and specific tumor-associated gene defects. This is best accomplished by evaluation of the patient's blood, bone marrow, and occasionally lymph node cells by a pathologist with specific training in blood disorders. A flow cytometer is necessary for cell marker analysis, and the detection of genetic problems in the cells may require visualizing the DNA changes with fluorescent probes by FISH.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "CLL treatment focuses on controlling and limiting the progress of the disease and its symptoms, as it remains incurable as of 2017. In patients with few to no symptoms, watchful waiting with close observation is generally appropriate.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Treatment is recommended when patients become symptomatic or experience one of the following:",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Dangerous drops in their red blood cell or platelet count",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "A doubling of their white blood cells in 6 months or less",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "As of 2024, first-line treatment for CLL involves the use of targeted biological therapy. Other treatment options include:  chemotherapy, radiation therapy, bone marrow transplantation, and supportive or palliative care.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Radiation therapy is usually only done in patients with SLL who have symptomatic localized disease, such as bulky lymph nodes. In special circumstances, patients can develop massive splenomegaly that may lead to the destruction of red blood cells, white blood cells, and platelets. In these cases, the patient may be treated with steroids or IVIG; however, if the patient does not respond to these treatments, they may have to undergo a splenectomy, removal of the spleen.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "CLL treatment regimens vary depending on the patient's age, physical health, and progression of their disease. There are several agents that may be used for the treatment of CLL.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Treatment approaches for SLL and CLL are usually the same.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "While it is generally considered incurable, CLL progresses slowly in most cases. Many people with CLL lead normal and active lives for many years\u2014in some cases for decades. Because of its slow onset, asymptomatic early-stage CLL (Rai 0, Binet A) is, in general, not treated since it is believed that early-stage CLL intervention does not improve survival time or quality of life. Instead, the condition is monitored over time to detect any change in the disease pattern.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "There are two widely used staging systems in CLL to determine when and how to treat the patient: The Rai staging system, used in the United States, and the Binet system in Europe. Both these systems attempt to characterize the disease based on the bulk and marrow failure.  A \"watchful waiting\" strategy is used for most patients with CLL.  The International Workshop on CLL (iwCLL) has issued guidelines with specific markers that should be met to initiate treatment, generally based on evidence for progressive symptomatic disease (summarized as \"active disease\").",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Targeted therapy attacks cancer cells at a specific target, with the aim of not harming normal cells. In patients with CLL, B-cell receptor (BCR) signaling appears to play a vital role in the growth and survival of CLL cells. BCR signaling is supported by a number of different tyrosine kinase inhibitors (such as BTK, PI3K, etc.), which can all be targeted in order to help interfere with the growth of these CLL cells. Another mechanism that CLL cells use to avoid destruction involves the use of proteins in the B-cell lymphoma (Bcl-2) family. By blocking the function of those Bcl-2 proteins, targeted drugs can prevent further progression of CLL-related tumors.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Some of the most common biological drugs used to treat CLL include:",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "CD20 is a protein that is found on the surface of B-cells and thus serves as an important target in the treatment of many B-cell malignances, including CLL. Some CD20 antibodies that have been used for the treatment of CLL include:",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "These agents are usually used in refractory/relapsed disease or in combination with other agents, like chlorambucil (CLB), fludarabine, or venetoclax.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Alemtuzumab targets the CD52 receptor, which is usually found on the surface of many immune cells. This agent is also primarily used in refractory disease.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Monotherapy using alkylating agents (i.e.  chlorambucil and bendamustine) served as a front-line therapy for CLL for many years. In fact, chlorambucil (CLB), was the \"gold standard\" treatment for CLL for several decades. However, researchers found that it was not very effective at helping patients achieve remission; thus, it may not be used as frequently in practice anymore.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Combination chemotherapy regimens can be effective in both newly diagnosed and relapsed CLL. Combinations of fludarabine with alkylating agents (cyclophosphamide) produce higher response rates and longer progression-free survival than single agents:",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Although the purine analogue fludarabine was shown to give superior response rates to chlorambucil (CLB) as primary therapy, the early use of fludarabine has not been shown to improve overall survival, and some clinicians prefer to reserve fludarabine for relapsed disease.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Chemoimmunotherapy with FCR has shown to improve response rates, progression-free survival, and overall survival in a large randomized trial in CLL patients selected for good physical fitness.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Autologous stem cell transplantation, using the recipient's own cells, is not curative.  Younger individuals, if at high risk for dying from CLL, may consider allogeneic hematopoietic stem cell transplantation (HSCT). Myeloablative (bone marrow killing) forms of allogeneic stem cell transplantation, a high-risk treatment using blood cells from a healthy donor, may be curative, but treatment-related toxicity is significant. An intermediate level, called reduced-intensity conditioning allogeneic stem cell transplantation, may be better tolerated by older or frail patients.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "\"Refractory\" CLL is a disease that no longer responds favorably to treatment within six months following the last cancer therapy. In this case, more aggressive targeted therapies, such as BCR or BCL2 pathway inhibitors, have been associated with increased survival.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Prognosis can be affected by the type of genetic mutation that the person with CLL has. Some examples of genetic mutations and their prognoses are: mutations in the IGHV region are associated with a median overall survival (OS) of more than 20\u201325 years, while no mutations in this region is associated with a median OS of 8\u201310 years; deletion of chromosome 13q is associated with a median OS of 17 years; and trisomy of chromosome 12, as well as deletion of chromosome 11q, is associated with a median OS of 9\u201311 years. While prognosis is highly variable and dependent on various factors including these mutations, the average 5-year relative survival is 89.3% in the US as of 2021. Telomere length has been suggested to be a valuable prognostic indicator of survival. In addition, a person's sex has been found to have an impact on CLL prognosis and treatment efficacy. More specifically, females have been found to survive longer (without disease progression) than males, when treated with certain medications.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "As of 2022, the most commonly used prognostic score is the CLL International Prognostic Index (CLL-IPI). This system takes into account the following factors:",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Clinical stage (see the Rai and Binet staging systems above)",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "CLL is the most common type of leukemia in the Western world compared to non-Western regions such as Asia, Latin America, and Africa. It is observed globally that males are twice as likely than females to acquire CLL. CLL is primarily a disease of older adults, with 9 out of 10 cases occurring after the age of 50 years. The median age of diagnosis is 70 years. In young people, new cases of CLL are twice as likely to be diagnosed in men than in women. In older people, however, this difference becomes less pronounced: after the age of 80 years, new cases of CLL are diagnosed equally between men and women.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "According to the American Cancer Society, they estimate that there will about 23,690 new cases of CLL with about 4,460 deaths from CLL in the United States throughout 2025. Five-year survival following diagnosis is approximately 89% in the United States as of 2021. It represents less than 1% of deaths from cancer.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Because of the prolonged survival, which was typically about 10 years in past decades, but which can extend to a normal life expectancy, the prevalence (number of people living with the disease) is much higher than the incidence (new diagnoses). CLL is the most common type of leukemia in the UK, accounting for 38% of all leukemia cases. Approximately 3,200 people were diagnosed with the disease in 2011.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "In Western populations, subclinical \"disease\" can be identified in 3.5% of normal adults, and in up to 8% of individuals over the age of 70. That is, small clones of B cells with the characteristic CLL phenotype can be identified in many healthy elderly persons. The clinical significance of these cells is unknown.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "CLL seems to be more rare in Asian countries, such as Japan, China, and Korea, accounting for less than 10% of all leukemias in those regions. A low incidence is seen in Japanese immigrants to the US, and in African and Asian immigrants to Israel.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Of all cancers involving the same class of blood cell, 7% of cases were CLL/SLL as of 2001.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "People who live near areas with considerable industrial pollution have an elevated risk of developing leukemia, particularly CLL.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "In light of newer targeted therapies such as Bruton tyrosine kinase inhibitors and anti-CD20 monoclonal antibodies, the need for bone marrow transplants in patients with CLL has become rare. Bone marrow transplants are only recommended in specific cases when front-line therapies have either failed and/or the patient continues to relapse.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "There have been major advances in the treatment of patients with CLL over the past 10 years or so. Although this disease remains incurable, therapies such as Bruton tyrosine kinase inhibitors (including ibrutinib, acalabrutinib, and zanubrutinib), BCL-2 inhibitors (including venetoclax), and phosphatidylinositol 3-kinase inhibitors (including idelalisib and duvelisib) allow patients with CLL to now live longer.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Despite the great success of these new targeted biological therapies so far, more research is needed in order to establish clearer guidelines on the optimal combination and sequence of these agents based on the patient's specific clinical presentation. Furthermore, for patients who do not respond to these agents, treatment options are limited. Thus, further research should be focused on discovering therapies that target other important chemical pathways.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Leukemia is rarely associated with pregnancy, affecting only about one in 10,000 pregnant women.  Treatment for chronic lymphocytic leukemias can often be postponed until after the end of the pregnancy.  If treatment is necessary, then giving chemotherapy during the second or third trimesters is less likely to result in pregnancy loss or birth defects than treatment during the first trimester.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Hairy cell leukemia is an uncommon hematological malignancy characterized by an accumulation of abnormal B lymphocytes. The incidence of hairy cell leukemia (HCL) is 0.28-0.30 cases per 100,000 people in Europe and the United States and the prevalence is approximately 3.12 cases per 100,000 in Europe with a lower prevalence in Asia, Africa and the Middle East.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "HCL has an indolent course but patients frequently relapse. Despite this, with treatment, life expectancy is usually the same as that for the general population.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "HCL was originally described as histiocytic leukemia, malignant reticulosis, or lymphoid myelofibrosis in publications dating back to the 1920s. The disease was formally named leukemic reticuloendotheliosis, and its characterization was significantly advanced by Bertha Bouroncle and colleagues at the Ohio State University College of Medicine in 1958.  Its common name, which was coined in 1966, is derived from the \"hairy\" appearance of the cytoplasmic projections from malignant B cells under a microscope.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "In HCL, the \"hairy cells\" (malignant B lymphocytes) accumulate in the bone marrow, interfering with the production of normal white blood cells, red blood cells, and platelets.  Consequently, patients may develop infections related to low white blood cell count, anemia and fatigue due to a lack of red blood cells, or easy bleeding due to a low platelet count.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Platelet function may be somewhat impaired in HCL patients, although this does not appear to have any significant practical effect.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Patients with a high tumor burden may also have somewhat reduced levels of cholesterol, especially in patients with an enlarged spleen.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Those with HCL rarely have constitutional symptoms such as fevers, chills, weight loss or rigors. 20-30% may have opportunistic infections due to an impairment in immune function. Rarely, in recurrent disease, bone lesions may be present which can be confused for other malignancies such as multiple myeloma.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "As with many cancers, the cause of HCL is unknown. Exposure to tobacco smoke, ionizing radiation, or industrial chemicals (with the possible exception of diesel) does not appear to increase the risk of developing it.  Farming and gardening correlate with an increased risk of HCL development in some studies which does not necessarily imply causation.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "A 2011 study identified somatic BRAF V600E mutations in all 47 HCL patients studied, and no such mutations in the 193 peripheral B-cell lymphomas/leukemias other than HCL.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "The U.S. Institute of Medicine (IOM) found a correlation which permits an association between exposure to herbicides and later development of chronic B-cell leukemias and lymphomas in general. The IOM report emphasizes that neither animal nor human studies indicate an association of herbicides with HCL specifically. However, the IOM extrapolated data from chronic lymphocytic leukemia and non-Hodgkin lymphoma to conclude that HCL and other rare B-cell neoplasms may share this risk factor.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Human T-lymphotropic virus 2 (HTLV-2) has been isolated in a small number of patients with the variant form of HCL. In the 1980s, HTLV-2 was identified in a patient with a T-cell lymphoproliferative disease; this patient later developed HCL, but HTLV-2 was not found in the hairy cell clones.  There is no evidence that HTLV-II causes any sort of hematological malignancy, including HCL.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "In a small population based study, there was an increased incidence of HCL in those who used or handled pesticides.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Pancytopenia in HCL is caused primarily by marrow failure and splenomegaly.  Bone-marrow failure is caused by the accumulation of hairy cells and reticulin fibrosis in the bone marrow, as well as by the detrimental effects of dysregulated cytokine production.  Splenomegaly reduces blood counts through sequestration, marginalization, and destruction of healthy blood cells inside the spleen.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Hairy cells are nearly mature B cells, which are activated clonal cells with signs of VH gene differentiation.  They may be related to pre-plasma marginal zone B cells or memory B cells.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Cytokine production is disturbed in HCL.  Hairy cells produce and thrive on TNF-alpha.  This cytokine also suppresses normal production of healthy blood cells in the bone marrow.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Unlike healthy B cells, hairy cells express and secrete an immune system protein called interleukin-2 receptor (IL-2R).  In HCL-V, only part of this receptor is expressed. As a result, disease status can be monitored by measuring changes in the amount of IL-2R in the blood serum.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Hairy cells respond to normal production of some cytokines by T cells with increased growth.  Treatment with interferon-alpha suppresses the production of this pro-growth cytokine from T cells.  A low level of T cells, which is commonly seen after treatment with cladribine or pentostatin, and the consequent reduction of these cytokines, is also associated with reduced levels of hairy cells.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Nearly all cases of HCL have the BRAF mutation V600E, and it is proposed that this is the disease's driver mutation. Until this point, only a few genomic imbalances had been found in the hairy cells, such as trisomy 5 had been found. The expression of genes is also dysregulated in a complex and specific pattern.  The cells underexpress 3p24, 3p21, 3q13.3-q22, 4p16, 11q23, 14q22-q24, 15q21-q22, 15q24-q25, and 17q22-q24 and overexpress 13q31 and Xq13.3-q21.  It has not yet been demonstrated that any of these changes have any practical significance to the patient.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "The diagnosis of HCL may be suggested by abnormal results on a complete blood count (CBC), but additional testing is necessary to confirm the diagnosis. A CBC normally shows low counts for white blood cells, red blood cells, and platelets in HCL patients.  However, if large numbers of hairy cells are in the blood stream, then normal or even high lymphocyte counts may be found.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "On physical examination, 80\u201390% of patients have an enlarged spleen, which can be massive.  This is less likely among patients who are diagnosed at an early stage.  Peripheral lymphadenopathy (enlarged lymph nodes) is uncommon (less than 5% of patients), but abdominal lymphadenopathy is a relatively common finding on computed tomography scans.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "The most important laboratory finding is the presence of hairy cells in the bloodstream.  Hairy cells are abnormal white blood cells with hair-like projections of cytoplasm; they can be seen by examining a blood smear or bone marrow biopsy specimen.  The blood film examination is done by staining the blood cells with Wright's stain and looking at them under a microscope.  Hairy cells are visible in this test in about 85% of cases. Along with the characteristic surface projections, hairy cells also have large amounts of cytoplasm, an oval (sometimes cleaved) nuclei with homogenous chromatin and no without distinct nucleoli giving the cells a \"fried egg\" appearance.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Most patients require a bone-marrow biopsy for final diagnosis.  The bone marrow biopsy is used both to confirm the presence of HCL and also the absence of any additional diseases, such as Splenic marginal zone lymphoma or B-cell prolymphocytic leukemia.  The bone marrow in HCL may show a diffuse infiltration of leukemic cells or an interstitial infiltration with partial preservation of fat and hematopoietic stem cells. The diagnosis can be confirmed by viewing the cells with a special stain known as tartrate resistant acid phosphatase (TRAP). More recently, DB44 testing assures more accurate results.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Definitively diagnosing HCL is also possible through flow cytometry on blood or bone marrow.  The hairy cells are larger than normal and positive for CD19, CD20, CD22, CD11c, CD25, CD103, and FMC7 antigens. (CD103, CD22, and CD11c are strongly expressed.)",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Annexin A1 and the BRAF v600E mutant protein are the most sensitive and specific cell markers associated with HCL. Diseases mimicking HCL are usually negative for both markers.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Hairy cell leukemia-variant (HCL-V), which shares some characteristics with B cell prolymphocytic leukemia (B-PLL), does not show CD25 (also called the interleukin-2 receptor, alpha).",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "The differential diagnoses include several kinds of anemia, including myelophthisis and aplastic anemia, and most kinds of blood neoplasms, including hypoplastic myelodysplastic syndrome, atypical chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, or idiopathic myelofibrosis.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "The \"classic\" form is often implied, but hairy cell leukemia-variant has also been described.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Hairy cell leukemia-variant (HCL-V) is usually described as a prolymphocytic variant of HCL.  It was first described in 1980.  About 10% of people with HCL have this variant form of the disease, representing about 60-75 new cases of HCL-V each year in the U.S.  While classic HCL primarily affects men, HCL-V is more evenly divided between males and females.  While the disease can appear at any age, the median age at diagnosis is over 70.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Similar to B-cell prolymphocytic leukemia (B-PLL) in chronic lymphocytic leukemia, HCL-V is a more aggressive disease.  Historically, it has been considered less likely to be treated successfully than is classic HCL, and remissions have tended to be shorter. The introduction of combination therapy with concurrent rituximab and cladribine therapy, though, has shown excellent results in early follow-up. As of 2016, this therapy is considered the first-line treatment of choice for many people with HCL-V.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Many older treatment approaches, such as interferon-alpha, the combination chemotherapy regimen \"CHOP\", and common alkylating agents such as cyclophosphamide, showed very little benefit. Pentostatin and cladribine administered as monotherapy (without concurrent rituximab) provide some benefit to many people with HCL-V, but typically induce shorter remission periods and lower response rates than when they are used in classic HCL.  More than half of people respond partially to splenectomy.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Higher white blood cell counts, sometimes exceeding 100,000 cells per microliter",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "A more aggressive course of disease requiring more frequent treatment",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Hairy cells with an unusually large nucleolus for their size",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Production of little excess fibronectin produced by classic hairy cells to interfere with bone marrow biopsies",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Low or no cell-surface expression of CD25 (interleukin-2 [IL-2] receptor alpha chain, or p55).",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Low levels of CD25, a part of the receptor for a key immunoregulating hormone, may explain why HCL-V cases are generally much more resistant to treatment by immune-system hormones.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "HCL-V, which usually features a high proportion of hairy cells without a functional p53 tumor suppressor gene, is somewhat more likely to transform into a higher-grade malignancy. A typical transformation rate of 5-6% has been postulated in the UK, similar to the Richter's transformation rate for splenic lymphoma with villous lymphocytes (SLVL) and CLL.  Among HCL-V patients, the most aggressive cases normally have the least amount of p53 gene activity.  Hairy cells without the p53 gene tend, over time, to displace the less aggressive p53(+) hairy cells.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Some evidence suggests that a rearrangement of the immunoglobulin gene VH4-34, which is found in about 40% of HCL-V patients and 10% of classic HCL patients, may be a more important poor prognostic factor than variant status, with HCL-V patients without the VH4-34 rearrangement responding about as well as classic HCL patients.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Several treatments are available, and successful control of the disease is common.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Not everyone requires treatment immediately. Due to the indolent nature of HCL, a \"watchful waiting\" approach may be done for those without significant cytopenia (low hemoglobin, absolute neutrophil count, and platelet count), symptomatic organomegaly, recurrent infections or constitutional symptoms. This watchful waiting approach is used in about 10-20% of people.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Purine analogs such as cladribine and pentostatin are the first-line therapies for HCL. Purine analogs are very effective in the treatment of HCL, achieving remission rates of 80-90%; with remission being defined as normal or near normal blood counts, no palpable splenomegaly and no hairy cells on bone marrow biopsy or peripheral blood without immunostaining, or minimal hairy cells with immunostaining (known as measurable residual disease). The benefits of treating measurable residual disease are not well established. The median relapse free time for purine analogs is greater than 10 years. The possible side effects of purine analogs include rash, fever, neutropenia, infections and a low T-cell counts (especially CD4+ T-cells). Purine analogs may cause immunosuppression over time and should not be used if the patients have an active infection.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Rituximab, the anti-CD20 monoclonal antibody, may be added to purine analogs during initial treatment and is associated with increasing the remission rate to nearly 100%. Purine analogs may be restarted in those with relapsed disease, with or without rituximab.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Cladribine can be administered by injection under the skin, by infusion over a few hours into a vein (intravenous - IV), or by a pump worn by the patient that provides a slow drip into a vein throughout the day.  Most patients receive cladribine by IV infusion once a day for five to seven days, but more patients are being given the option of taking this drug once a week for six weeks.  The different dosing schedules used with cladribine are roughly equally effective and safe. Relatively few patients have significant side effects other than fatigue and a high fever caused by the cancer cells dying, although complications such as infection and acute kidney failure have been seen.  Pentostatin is chemically similar to cladribine, and has a similar success rate and side effect profile, but it is always given over a much longer period of time, usually one dose by IV infusion every two weeks for 3\u20136 months.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "During the weeks following treatment, the patients' immune systems are severely weakened, but their bone marrow will begin to produce normal blood cells again.  Treatment often results in long-term remission. If the cancer cells return, the treatment may be repeated and should again result in remission, although the treatment response may decline with repeated treatment.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Cladribine induced complete responses in patients with hairy cell leukemia resistant to pentostatin, suggesting a lack of cross-resistance..",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "If a patient is resistant to either cladribine or pentostatin, or in those with relapsed disease, then second-line therapy is pursued.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "BRAF inhibitors such as vemurafenib or dabrafenib inhibit the MAPK/ERK pathway which is constitutively active in those with a BRAF V600E kinase activating mutation (which is 95% of those with HCL). Constitutively active MAPK kinase activity is what leads to disease activity in HCL by increasing cell survival, increasing proliferation and reducing apoptosis of the leukemic cells. BRAF inhibitors have an overall response rate of greater than 90% with a complete response of 30-35% in people with relapsed or refractory HCL. They are also known to have less toxic effects than the purine analogs. They may be combined with rituximab to increase the remission rate. The median duration of response with BRAF inhibitors is 1.5 years (more than 3 years if combined with rituximab), after which remission occurs. BRAF inhibitors with or without rituximab may be restarted if there is relapsed disease.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Ritixumab: Two partial and 10 complete responses resulted from 15 patients with relapsed disease, for a total of 80% responding.  The median response time is greater than 3 years.  Rituximab has successfully induced a complete response in Hairy Cell-Variant.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Rituximab may cause a serum sickness reaction which presents with fevers, joint pain and rash approximately 4-10 days after any infusion. The reaction is successfully treated with steroids.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "If progression of disease or relapse is seen in those previously on BRAF inhibitors plus rituximab, the combination can be retried. Or the anti-CD22 immunotoxin moxetumomab pasudotox can be tried. Or a BRAF inhibitor can be restarted plus MEK inhibitors trametinib or cobimetinib.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Interferon-alpha is an immune system hormone that is very helpful to a relatively small number of patients, and somewhat helpful to most patients.  In about 65% of patients, the drug helps stabilize the disease or produce a slow, minor improvement for a partial response. Some patients can achieve the negativization of minimal residual disease by BRAF-V600E status",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Some patients tolerate IFN-alpha very well after the first few weeks, while others find that its characteristic flu-like symptoms persist.  About 10% of patients develop a level of depression.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "A drop in blood counts is usually seen during the first 1\u20132 months of treatment.  Most patients find that their blood counts get worse for a few weeks immediately after starting treatment, although some patients find their blood counts begin to improve within just 2 weeks.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Typically, 6 months are needed to figure out whether this therapy is useful.  Common criteria for treatment success include:",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "A normal or somewhat low platelet count (above 100 K/\u03bcL), and",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "A normal or somewhat low absolute neutrophil count (above 1.5 K/\u03bcL).",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "IFN-alpha is considered the drug of choice for pregnant women with active HCL.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "IFN-alpha works by sensitizing the hairy cells to the killing effect of the immune-system hormone TNF-alpha, whose production it promotes.  IFN-alpha works best on classic hairy cells that are not protectively adhered to vitronectin or fibronectin, which suggests that patients who encounter less fibrous tissue in their bone-marrow biopsies may be more likely to respond to IFN-alpha therapy.  It also explains why unadhered hairy cells, such as those in the bloodstream, disappear during IFN-alpha treatment well before reductions are seen in adhered hairy cells, such as those in the bone marrow and spleen.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Splenectomy (once commonly used in the treatment of HCL) has been replaced by purine analogs and other first line therapies, which are associated with greater response rates and a longer response. But splenectomy may still be done when other therapies fail and there is a large disease burden (clonal B cells) in the spleen.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "People with low numbers of red blood cells or platelets may also receive red blood cells and platelets through blood transfusions. Affected people may also receive a hormone to stimulate production of red blood cells.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "People with low neutrophil counts may be given filgrastim or a similar hormone to stimulate production of white blood cells.  However, a 1999 study indicates that routine administration of this expensive injected drug has no practical value for HCL patients after cladribine administration.  In this study, patients who received filgrastim were just as likely to experience a high fever and to be admitted to the hospital as those who did not, even though the drug elevated their white blood cell counts.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Hematopoietic stem cell transplantation for HCL does not improve relapse free survival at 5 years and is associated with a high mortality rate above 15% and is not recommended.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "More than 95% of new patients are treated well or at least adequately by cladribine or pentostatin.  A majority of new patients can expect a disease-free remission time span of about ten years, or sometimes much longer after taking one of these drugs just once.  If retreatment is necessary in the future, the drugs are normally effective again, although the average length of remission is somewhat shorter in subsequent treatments.  There is also the risk of Shingles, and Peripheral Neuropathy after treatment with cladribine.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "As with B-cell chronic lymphocytic leukemia, mutations in the IGHV on hairy cells are associated with better responses to initial treatments and with prolonged survival.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "How soon after treatment a patient feels \"normal\" again depends on several factors, including:",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "how advanced the disease was at the time of treatment;",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "whether the patient had a \"complete response\" or only a partial response to the treatment;",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "whether the patient experienced any of the rare, but serious side effects such as kidney failure;",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "whether the patient is experiencing unusual psychological trauma from the \"cancer\" diagnosis; and",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "how the patient perceived his or her pre-treatment energy level and daily functioning.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "With appropriate treatment, the overall projected lifespan for patients is normal or near-normal.  In all patients, the first two years after diagnosis have the highest risk for fatal outcome; generally, surviving five years predicts good control of the disease.  After five years' clinical remission, patients in the United States with normal blood counts can often qualify for private life insurance with some US companies.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Accurately measuring survival for patients with the variant form of the disease (HCL-V) is complicated by the relatively high median age (70 years old) at diagnosis.  However, HCL-V patients routinely survive for more than 10 years, and younger patients can likely expect a long life.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Despite decade-long remissions and years of living very normal lives after treatment, hairy cell leukemia is officially considered an incurable disease.  While survivors of solid tumors are commonly declared to be permanently cured after two, three, or five years, people who have hairy cell leukemia are never considered 'cured'.  Relapses of HCL have happened even after more than twenty years of continuous remission.  Patients will require lifelong monitoring and should be aware that the disease can recur even after decades of good health.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "While most oncologists consider Hairy Cell Leukemia to be incurable, there is some evidence that some patients are in fact cured after treatments.   Of the original 358-patient cohort treated with cladribine at the Scripps Clinic, 9 of 19 in continuous CR for a median of 16 years were free of HCL \u2014 even sensitive testing for measurable or minimal residual disease (MRD) found an absence of hairy cells. This suggests that the disease of at least some patients may be cured.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "People in remission need regular follow-up examinations after their treatment is over.  Most physicians insist on seeing patients at least once a year for the rest of the patient's life, and getting blood counts about twice a year.  Regular follow-up care ensures that patients are carefully monitored, any changes in health are discussed, and new or recurrent cancer can be detected and treated as soon as possible. Between regularly scheduled appointments, people who have hairy cell leukemia should report any health problems, especially viral or bacterial infections, as soon as they appear.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "HCL patients are also at a slightly higher than average risk for developing a second kind of cancer,  such as colon cancer or lung cancer, at some point during their lives (including before their HCL diagnosis).  This appears to relate best to the number of hairy cells, and not to different forms of treatment.  On average, patients might reasonably expect to have as much as double the risk of developing another cancer, with a peak about two years after HCL diagnosis and falling steadily after that, assuming that the HCL was successfully treated.  Aggressive surveillance and prevention efforts are generally warranted, although the lifetime odds of developing a second cancer after HCL diagnosis are still less than 50%.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "There is also a higher risk of developing an autoimmune disease. Polyarteritis nodosa has been associated with underlying hairy cell leukemia in certain cases. Autoimmune diseases may also go into remission after treatment of HCL.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "HCL is more common in men, with the male to female distribution is 4 to 1, and the median age at diagnosis is age 55-60. It does not occur in children. The incidence in the United States and Europe is 0.28-0.3 cases per 100,000, and the prevalence is 3 cases per 100,000people  in Europe. It is less common in Africa, the Middle East and Asia.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "It does not appear to be hereditary, although rare familial cases that suggest a predisposition have been reported, usually showing a common Human Leukocyte Antigen (HLA) type.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "The Hairy Cell Leukemia Consortium was founded in 2008 to address researchers' concerns about the long-term future of research on the disease.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "In 2013 the Hairy Cell Leukemia Foundation was created when the Hairy Cell Leukemia Consortium and the Hairy Cell Leukemia Research Foundation joined. The HCLF is dedicated to improving outcomes for patients and advancing research into HCL.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Three immunotoxin drugs have been studied in patients at the NIH National Cancer Institute in the U.S.:  BL22, HA22 and LMB-2.  All of these protein-based drugs combine part of an anti-B cell antibody with a bacterial toxin to kill the cells on internalization.  BL22 and HA22 attack a common protein called CD22, which is present on hairy cells and healthy B cells.  LMB-2 attacks a protein called CD25, which is not present in HCL-variant, so LMB-2 is only useful for patients with classic HCL.  HA-22, now renamed moxetumomab pasudotox, is being studied in patients with relapsed hairy cell leukemia.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "Other clinical trials are studying the effectiveness of cladribine followed by rituximab in eliminating residual hairy cells that remain after treatment by cladribine or pentostatin.  It is not currently known if the elimination of such residual cells will result in more durable remissions.",
    "date": null,
    "verdict": null
  },
  {
    "source": "wikipedia",
    "text": "The major remaining research questions are identifying the cause of HCL and determining what prevents hairy cells from maturing normally.",
    "date": null,
    "verdict": null
  }
]